Diabetes

PHER-O2 used to transport pancreas islet cells transplanted into humans

Published in Obesity and Diabetes Week, December 27th, 2004

Sanguine Corporation (SGNC) announced that its product, PHER-O2, was used to transport pancreas islet cells transplanted into two humans at the University of Alberta in Edmonton, Canada.

The University's two human islet cell transplants were an unqualified success. These trials, conducted by the University, are for the use of PHER-O2 in the transportation and transplantation of pancreas islet cells.

A second group of 20 samples of PHER-O2 has recently been delivered to the University.

Thomas Drees, PhD, chairman and chief executive officer of Sanguine Corporation, stated, "...Diabetes is the fastest growing chronic disease in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-12-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry